Data presented by UCLA researcher Dr. Pinchas Cohen at the Pediatric Academic Societies' 2005 annual meeting in Washington, D.C., demonstrated that non-growth hormone deficient primary insulin-like ...
BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 3, 2006--Tercica, Inc. (Nasdaq:TRCA) today announced the U.S. commercial launch of Increlex(TM) (mecasermin (rDNA origin ...
San Diego, CA – June 6, 2005 – Tercica, Inc. (Nasdaq: TRCA) announced today that it presented data from several studies in poster sessions at the 87th Annual Meeting of the Endocrine Society. Some of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Mecasermin, when administered at the highest end of the ...
Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions Acquisition to Bolster Eton’s Commercial Pediatric Endocrinology ...
Acquisition bolsters Eton’s commercial pediatric endocrinology portfolio Product is now available through AnovoRx, a specialty pharmacy dedicated to serving patients with rare and chronic conditions ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results